KPTI

Karyopharm Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality7/10
  • Growth↓ 0/10
  • Momentum↑ 8/10
Karyopharm Therapeutics sales and earnings growth
KPTI Growth
Low
  • Revenue Y/Y↓ 0.57%
  • EPS Y/Y↓ -90.54%
  • FCF Y/Y↑ 40.95%
Karyopharm Therapeutics gross and profit margin trends
KPTI Profitability
Neutral
  • Gross margin ↑ 95.90%
  • EPS margin↓ -134.20%
  • ROIC↓ -86.00%
Karyopharm Therapeutics net debt vs free cash flow
KPTI Risk
Great
  • Debt / Equity↓ -0.8
  • Debt / FCF↓ 2.3
  • Interest coverage↓ -3.3

Karyopharm Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗